EMA Withdrawn: Ribavirin Mylan (previously Ribavirin Three Rivers) (ribavirin) — Mylan S.A.S

View source ↗

Summary

The EMA has withdrawn Ribavirin Mylan (ribavirin) from the market (formerly Ribavirin Three Rivers).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Hepatitis

Drugs mentioned

• Ribavirin Mylan (ribavirin)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Mylan S.A.S. Decision date: 13/03/2019